Engflag

Phosphocol

Quick links to important sections

Phosphocol

Phosphocol_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phosphocol

Property Description
Active Ingredient Phosphorus P-32 (as Chromic Phosphate)
Form Sterile Aqueous Suspension (Injection)
Pharmacological Class Therapeutic Radiopharmaceutical
General Purpose To deliver targeted local irradiation
Origin Synthetic Radioisotope

What Type of Medicine is Phosphocol P-32?

Chromic Phosphate P-32, also identified as Phosphocol P-32, is a highly specialized, prescription-only drug officially categorized as a therapeutic radiopharmaceutical. This classification signifies that its therapeutic effect is primarily derived from controlled radiation rather than chemical mechanisms alone. The drug utilizes the Phosphorus P-32 radioisotope, which is a synthetic material manufactured specifically for medical application. Its unique status as an injectable radiopharmaceutical is clinically recognized for its utility in certain targeted interventions, distinguishing it from standard, systemically absorbed agents.

Composition and Form: The Sterile Aqueous Suspension

The active component, the isotope Phosphorus P-32, is bound within a Chromic Phosphate compound and supplied as a sterile aqueous suspension. This preparation is not a simple solution but a fine particulate mixture suspended in a water-based vehicle, including excipients like dextrose solution and sodium acetate. The form is specifically prepared for localized delivery via intracavitary instillation or interstitial injection, and is not intended for oral use. The particulate nature of the suspension is essential for ensuring the active material adheres to the treatment surfaces, preventing rapid dispersal.

General Purpose: Targeted Local Irradiation

The fundamental function of Chromic Phosphate P-32 is to provide targeted local irradiation to tissues where it is placed. The Phosphorus P-32 component is a beta emitter, releasing high-energy, short-range beta particles. This intense but physically confined field of radiation leads to local cell disruption within a short radius of the compound. The general therapeutic goal of this process is the inhibition of excessive or unwanted cell proliferation in confined spaces, a typical use scenario when managing fluid buildup in large body cavities, utilizing a highly contained method of intervention.

Regulatory References

  1. DailyMed Product Information

What side effects are possible with Phosphocol?

Possible Side Effects and Safety Information

The safety profile of Phosphocol (Chromic Phosphate P 32 Suspension) is based on reported adverse reactions and official regulatory warnings concerning its use as a radiopharmaceutical.

Adverse Reactions Reported

Side effects documented in regulatory sources are generally classified as either localized (at the site of administration) or systemic (affecting the body more generally). Frequency information for most reactions is not available from official post-marketing reports.

Category Documented Adverse Reactions
Systemic Effects Transitory radiation sickness, bone marrow depression, nausea, abdominal cramping, weakness, fatigue, anorexia, diarrhea, vomiting.
Local Effects Pleuritis (inflammation of the lung lining), peritonitis (inflammation of the abdominal lining), radiation damage (e.g., severe local necrosis or fibrosis).

Serious Adverse Reactions and Safety Warnings

  • Secondary Malignancy Risk: Acute lymphocytic leukemia has been reported in children following the intra-articular administration of Phosphocol P 32 for a non-indicated use. The drug is not indicated for this route of administration, and safety and effectiveness in pediatric patients have not been established.
  • Severe Local Injury: Intestinal fibrosis or necrosis and chronic fibrosis of the body wall have been reported to result from the unintended misplacement of the therapeutic agent (e.g., into the bowel lumen or body wall) during administration.

Safety Restrictions and Contraindications

Official regulatory documents place restrictions on the use of Phosphocol due to safety concerns:

  • Pregnancy and Lactation: The medicine should not be administered to patients who are pregnant or lactating unless the potential therapeutic benefits outweigh the potential hazards.
  • Contraindications: Use is prohibited in the presence of ulcerative tumors. Administration is also not recommended in exposed cavities or where there is evidence of loculation (pockets of fluid) unless the extent of loculation has been determined.

Overdose and Emergency Response

Overdose and when to seek help

For the therapeutic radiopharmaceutical Chromic Phosphate P-32 (Phosphocol P-32), the risk of overdose is defined by the consequences of misplacement or excessive local radiation exposure, as documented in regulatory information. This is distinct from a chemical overdose.

Documented Manifestations and Severe Outcomes

Official labeling describes that overexposure can lead to severe local radiation injury. Specific manifestations reported include intestinal fibrosis or necrosis and chronic fibrosis of the body wall when the material is misplaced within body cavities. Systemic toxicity is documented as bone marrow depression, which is a severe outcome. Transitory effects such as nausea and abdominal cramping or signs of peritonitis may also be noted.

Required Emergency Actions

Immediate medical attention must be sought if signs indicating severe toxicity or radiation injury occur. This includes any unusual bleeding or bruising (indicating bone marrow effects) or severe abdominal/stomach pain (signifying potential tissue necrosis). The management of overexposure is limited to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known.

Population-Specific Considerations

The official warnings note an increased risk of leukemia in children following administration by routes not approved in the labeling, highlighting a population-specific, long-term severe risk of radiation overexposure.

Therapeutic Uses of Phosphocol

What Phosphocol Treats: Main Uses and Benefits

Phosphocol P-32 is a specialized therapeutic agent relevant in clinical settings for management of conditions presenting with significant symptomatic burden. It is applied across therapeutic domains where additional symptomatic support is needed. This treatment may assist with easing the patient's overall symptom load and supports general well-being during difficult episodes.

The primary therapeutic use is in managing symptomatic fluid overload (malignant effusions) in large body cavities, such as the peritoneum and pleura, typically in contexts involving chronic, metastatic disease. It is also considered relevant for managing manifestations of specific tumor and cystic disease, including certain cases of ovarian cancer and prostatic disease, and for specialized treatment of chronic, refractory synovitis. This use helps address symptom clusters that may become intense or disruptive due to the physical presence or recurrence of the growth.

Applying this treatment supports patients during symptomatic periods by easing distress related to severe shortness of breath or abdominal discomfort, and may assist with supporting functional stability during localized disease management.

Quick Fact: Relief for Symptomatic Fluid Overload

Phosphocol P-32 is commonly used in scenarios where symptoms intensify due to recurrent malignant effusions, and supportive relief is needed to ease the physical discomfort and functional stress caused by excessive fluid buildup.

Regulatory References

  1. DailyMed Product Information for Phosphocol P-32

Eligibility and Restrictions for Use

Who Can and Cannot Use Phosphocol P-32

Official regulatory documents define strict eligibility criteria for the use of Chromic Phosphate P-32, focusing on specific anatomical conditions, patient populations, and proper administration. This information is derived exclusively from government labeling.

Absolute Contraindications and Prohibited Use

The medicine must not be used in patients with ulcerative tumors or when administration would be made into exposed cavities. Use is also strictly prohibited where there is significant evidence of loculation unless the extent of the loculation is first determined by pre-assessment. Furthermore, Chromic Phosphate P-32 is not for intravascular injection under any circumstances, limiting administration to intracavitary or interstitial routes.

Age and Reproductive Status Restrictions

Safety and effectiveness have not been established in pediatric patients, meaning the drug is generally restricted to the adult population for approved indications. Use in pregnant or lactating patients is not recommended unless the treating physician determines that the potential therapeutic benefits outweigh the documented hazards. If a nursing mother is treated, permanent discontinuation of breastfeeding is necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Chromic Phosphate P-32 (Phosphocol P-32) is defined by the absence of specific, documented systemic drug-drug interactions. As a specialized therapeutic radiopharmaceutical, Phosphocol is administered as a sterile suspension intended for localized delivery via intracavitary or interstitial instillation to provide targeted irradiation.

Official Regulatory Interaction Profile

Interaction Type Status in Regulatory Labeling
Pharmacokinetic (PK) Interactions None documented. No data exists regarding metabolism via Cytochrome P450 (CYP) enzymes or drug transporter modulation (e.g., P-gp), consistent with the drug’s minimal systemic absorption.
Pharmacodynamic (PD) Interactions None documented. Official prescribing information does not list additive or synergistic pharmacological effects with co-administered medicines.
Food, Alcohol, or Supplements None documented. Official labeling does not specify any known interactions with food, alcohol, or herbal products.

Consequently, the official labeling contains no formal restrictions requiring time separation between the administration of Phosphocol P-32 and other medicinal products based on metabolic or kinetic interaction risks. There are no specific combinations classified as contraindicated due to drug interaction mechanisms. The absence of a detailed systemic drug-interaction section aligns with its therapeutic mechanism, which relies on confined radiation rather than systemic chemical activity.

Mechanism of Action

How Phosphocol Works

Phosphocol is a targeted pharmacological agent that exerts its effects by engaging specific receptor- and enzyme-mediated signaling pathways. Its primary pharmacodynamic action is to modulate key pathways associated with heightened or dysregulated physiological responses, which modifies the activity ratio of key molecular regulators within the affected biological system.

Modulation of Specific Signaling Cascades

Phosphocol initiates changes by modifying early molecular steps, specifically by initiating or suppressing signaling sequences that lead to downstream functional effects. This intervention is relevant in cascades where multiple layers of pathway activation occur, and influences feedback regulation to support a more controlled process, resulting in corresponding shifts in physiological parameters.

Regulation of Mediator Activity

The compound primarily affects systems where specific transmitters or mediators dominate. By engaging these mechanisms, Phosphocol regulates the activity of processes driven by distinct signaling patterns. This mechanistic domain reduces the functional consequence of excessive mediator activity and alters the magnitude of downstream signaling outputs.

Dosage and Administration Information

How Phosphocol is Used

Phosphocol P-32, a specialized therapeutic radiopharmaceutical, is administered only through highly localized procedures. The approved methods are intracavitary instillation or interstitial injection; the drug is specifically not for intravascular injection. Due to its nature, administration is reserved exclusively for a qualified physician with specialized training in the safe handling and use of radionuclides, ensuring careful placement.

Administration and Dosage Principles

The dosage of Chromic Phosphate P-32 is calculated specifically for the site of instillation. For administration into the abdominal cavity (intraperitoneal instillation), the typical labeled dose range is 370 to 740 megabecquerels (MBq), while the dose for the chest cavity (intrapleural instillation) is lower, ranging from 222 to 444 MBq. In cases of localized interstitial use, the dose is determined based on the estimated weight of the target tissue, typically using a range of 3.7 to 18.5 MBq per gram.

Preparation and Schedule

As the medication is supplied as a sterile aqueous suspension, the vial must be shaken well immediately before the dose is measured to ensure the uniform distribution of the chromic phosphate particles. Treatment with Phosphocol P-32 follows an intermittent, event-driven schedule, delivered only as a single intervention tied to a specific clinical requirement. It is not a medication used on a fixed daily or weekly regimen. The safety and effectiveness of this medicine have not been established in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Phosphocol

Phosphocol (Chromic Phosphate P-32) was studied for its use in specific, localized conditions. The evidence base primarily consists of clinical reports and observational studies conducted over many decades. Studies help show what has been observed so far in specific groups of patients, offering context about how these localized procedures was evaluated in various settings.

Evidence for Symptom Management in Malignant Effusions

Research has explored the use of this radiopharmaceutical as a treatment applied in studies examining patient-reported outcomes describing perceived discomfort related to recurrent fluid accumulation in body cavities, such as the chest (pleural) and abdomen (peritoneal). Early clinical studies and non-randomized reports were evaluated in patients with conditions involving periods of heightened symptoms caused by advanced cancer.

Investigators tracked measurements related to outcomes related to systemic or functional imbalance and monitored how fluid accumulation was observed in the treated cavities. Findings describe patterns observed in the studies where local application was associated with observed changes in symptoms such as shortness of breath and abdominal pressure. Some research explored whether patterns of fluid control may differ when effusions contained significant blood.

What remains uncertain in this area is how these results compare to modern, systemic treatment options. The evidence quality varies across studies, with many reports predating the current standard for large-scale, controlled trials.

Research for Localized Tumor and Carcinoma Management

Research examined the use of this agent in studies focusing on episodes where symptoms become more noticeable in localized cancers, particularly certain cases of ovarian and prostatic carcinoma. These investigations involved clinical treatment regimens where the radiopharmaceutical was studied for localized administration, often in conjunction with other standard anti-cancer treatments. Studies monitored outcomes reflecting daily functioning or activity level and tracked long-term patterns; research describes survival patterns as outcomes monitored over multiple years.

Studies for Chronic Refractory Synovitis

The evidence structure for using this agent was studied for outcomes linked to inflammatory or irritative states, such as chronic refractory synovitis (joint inflammation), in long-term retrospective studies and observational patient series. Findings describe patterns observed in the studies where research examined changes in the frequency of joint bleeding episodes and monitored patient-reported outcomes for pain and mobility, with some follow-up extending for over a decade.

Key Studies & References

  1. DailyMed Product Information for Chromic Phosphate P-32 (Phosphocol)
  2. Radiopharmaceuticals in Oncology: Applications and Clinical Efficacy (NIH/NCI Review)

Frequently Asked Questions (FAQ)

Common questions about Phosphocol (FAQ)

Q: What is the main reason doctors prescribe Phosphocol?

A: According to official product information, Phosphocol is prescribed as a therapeutic radiopharmaceutical. Its purpose is the localized treatment of effusions, which is fluid buildup in body cavities like the abdomen or chest caused by metastatic disease. It has also been studied for localized treatment of certain specific carcinomas.

Q: What are the most commonly reported side effects of Phosphocol?

A: Regulatory documents indicate that commonly reported systemic side effects include general discomfort, weakness, loss of appetite (anorexia), and fatigue. Some patients may also experience reactions such as nausea, vomiting, diarrhea, and abdominal cramping. This information is derived from documented adverse reactions reported in studies, but official labeling generally does not include frequency data.

Q: Is Phosphocol safe for older adults (seniors)?

A: Official documents state there is no specific data available that compares the use of Phosphocol in elderly patients with its use in younger adult groups. However, the medicine is not expected to cause different side effects or unique problems in older people than those observed in other adult populations.

Q: What does the term 'radioactive tracer' mean in the context of Phosphocol?

A: Phosphocol is officially classified as a therapeutic radiopharmaceutical, which is a type of medicine that delivers controlled radiation for treatment purposes. This differs from a 'radioactive tracer,' which is a diagnostic agent used for imaging.

Q: Why is Phosphocol given as an injection instead of a pill?

A: Phosphocol is formulated as a sterile aqueous suspension intended for highly localized delivery into a body cavity (instillation) or specific tissue (interstitial injection). Official documents specify that the drug is not for oral use (as a pill) and is restricted to administration by specialized injection or instillation, as its mechanism requires precise, targeted placement.

Q: What is the shelf-life or expiration date for Phosphocol?

A: The drug's shelf-life is inherently linked to the radioactive decay of its active component, Phosphorus P-32. This isotope has a physical half-life of approximately 14.3 days, meaning its therapeutic activity decreases by half every two weeks.

Q: How does the FDA classify Phosphocol's safety?

A: The FDA classification for this drug is a Therapeutic Radiopharmaceutical or Radioactive Therapeutic Agent. Official safety documents describe warnings concerning the risk of secondary malignancy (a new cancer) and the potential for severe local injury if the medicine is misplaced during administration.

Q: What are the key findings from the clinical trials of Phosphocol?

A: Studies and official reports have examined the use of the drug in managing symptoms associated with recurrent fluid buildup (effusions) in body cavities related to metastatic disease. Research has also monitored patient outcomes and survival patterns following localized treatments for specific carcinomas.

Q: What should be done if I experience an allergic reaction to Phosphocol?

A: Official safety information indicates that if any unusual or allergic reaction is experienced, the specialized healthcare professional or doctor who administered the medicine should be informed immediately. They will determine the necessary immediate care.

Q: Does Phosphocol make you 'glow' or set off radiation detectors?

A: Phosphocol is a pure beta particle emitter. Based on the drug's physical properties, the beta particles have a very short range in tissue. This short range means the radiation would not be visually noticed and is unlikely to trigger standard external radiation detectors used in public spaces.

Q: How long does Phosphocol stay in the body after injection?

A: The active radiation level decreases over time based on the physical half-life of Phosphorus P-32, which is approximately 14.3 days. The specific time it takes for the body to biologically eliminate the entire compound is separate from this physical decay rate and is not generally listed in the main regulatory documents.

Q: Are there different brand names for the same medicine as Phosphocol?

A: Yes, the active drug, Chromic Phosphate P-32, is marketed under the trade name Phosphocol P-32. Official documents and scientific literature also refer to it by other names, such as Chromphosphotope.

Q: What does 'contraindicated' mean for Phosphocol?

A: When a condition is listed as contraindicated for Phosphocol, it means that the risk of using the drug under those specific circumstances is known to outweigh any possible therapeutic benefit. The official prescribing information mandates that the medicine must not be administered under those conditions.

Q: Why is Phosphocol only used in specialized medical settings?

A: Phosphocol is restricted to use in specialized medical settings because it is a therapeutic radiopharmaceutical that delivers targeted radiation. Administration must be performed by a healthcare provider specialized in nuclear medicine or a qualified physician with training in the safe handling and accurate placement of radionuclides.

Q: What is the difference between a tracer and a therapeutic drug?

A: A therapeutic radiopharmaceutical, such as Phosphocol, is intended to deliver targeted, local radiation to affected tissue. In contrast, a tracer or diagnostic agent uses low-level radiation for imaging purposes to help study the function of the body's organs.

Q: What precautions are needed for close contact with others after receiving Phosphocol?

A: The medical team will provide specific post-treatment radiation safety instructions tailored to the patient and procedure. Due to the drug’s properties as a localized radiopharmaceutical, these precautions often focus on limiting close or extended contact exposure to bodily fluids for a specified period of time.

How should Phosphocol be stored and disposed of?

How to Store and Dispose of Phosphocol P 32

The storage and disposal of Chromic Phosphate P 32 Suspension are strictly governed by regulations for radiopharmaceuticals.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Protection Do not freeze the sterile aqueous suspension.
Security Keep licensed material secured from unauthorized removal, ensuring it is out of the reach of children.

Handling and Disposal

Handling and administration must be performed only by licensed personnel using appropriate shielding and radiation safety precautions. The drug's shelf-life is inherently tied to the radioactive decay of the Phosphorus P 32 isotope.

Disposal of unused or expired product must be managed as radioactive waste according to the protocols set by the regulatory authority, which often includes procedures like decay-in-storage.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Phosphocol found in:

A-Z Index: